Literature DB >> 21495220

Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer: is radiological staging sufficient for planning conservative treatment?

Thomas J Cade1, Michael A Quinn, Orla M McNally, Deborah Neesham, Jan Pyman, Andrew Dobrotwir.   

Abstract

OBJECTIVES: There has been an increasing interest in accurately assessing tumors preoperatively to plan appropriate surgery or, in some low-risk patients, conservative treatment. We wish to determine the accuracy of magnetic resonance imaging (MRI) in predicting myometrial invasion in endometrial cancer and whether it is a safe and suitable tool for planning conservative treatment.
MATERIALS AND METHODS: We compared MRI scans and final histopathologic diagnoses of 111 patients with endometrioid adenocarcinoma over a 6-year period at a major tertiary centre. Data were analyzed collectively and according to histological differentiation and types of MRI scans (1.5 vs 3 T). Outcomes were presence versus absence of myometrial invasion and recently revised International Federation of Gynecology and Obstetrics stage IA (up to 50% myometrial invasion) versus deep invasion.
RESULTS: Magnetic resonance imaging had a high negative predictive value for the presence of deep invasion (87% overall and 95% for grade 1 disease). However, although the positive predictive value for the presence of any myometrial invasion was high, negative predictive values were poor (35% for all grades and 46% for grade 1). There was no difference between 1.5- and 3-T scanning.
CONCLUSIONS: Magnetic resonance imaging is a suitable screening tool for the presence of stage IA disease under the newly revised International Federation of Gynecology and Obstetrics staging system. The significance of this finding will depend on whether clinicians are willing to treat all grade 1 stage IA disease (under the revised system) as low risk and to deem selected patients in this group suitable for more conservative treatment.

Entities:  

Mesh:

Year:  2010        PMID: 21495220     DOI: 10.1111/igc.0b013e3181e9509f

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  An MRI radiomics nomogram improves the accuracy in identifying eligible candidates for fertility-preserving treatment in endometrioid adenocarcinoma.

Authors:  Bi-Cong Yan; Feng-Hua Ma; Ying Li; Yan-Feng Fan; Zhi-Long Huang; Xiao-Liang Ma; Xue-Ting Wen; Jin-Wei Qiang
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

2.  Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer.

Authors:  Gaiane M Rauch; Harmeet Kaur; Haesun Choi; Randy D Ernst; Ann H Klopp; Piyaporn Boonsirikamchai; Shannon N Westin; Leonardo P Marcal
Journal:  Radiographics       Date:  2014 Jul-Aug       Impact factor: 5.333

3.  Imaging across the life span: innovations in imaging and therapy for gynecologic cancer.

Authors:  Meng Xu-Welliver; William T C Yuh; Julia R Fielding; Katarzyna J Macura; Zhibin Huang; Ahmet S Ayan; Floor J Backes; Guang Jia; Mariam Moshiri; Jun Zhang; Nina A Mayr
Journal:  Radiographics       Date:  2014 Jul-Aug       Impact factor: 5.333

4.  Cancer of the corpus uteri: 2021 update.

Authors:  Martin Koskas; Frédéric Amant; Mansoor Raza Mirza; Carien L Creutzberg
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

5.  A novel model to estimate lymph node metastasis in endometrial cancer patients.

Authors:  Cristina Anton; Alexandre Silva E Silva; Edmund Chada Baracat; Nasuh Utku Dogan; Christhardt Köhler; Jesus Paula Carvalho; Giovanni Mastrantonio di Favero
Journal:  Clinics (Sao Paulo)       Date:  2017-01-01       Impact factor: 2.365

6.  Adjuvant vaginal brachytherapy as a part of management in early endometrial cancer.

Authors:  Sylwia Kellas-Ślęczka; Piotr Wojcieszek; Brygida Białas
Journal:  J Contemp Brachytherapy       Date:  2012-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.